One of the hallmarks of tumor cells is genetic rearrangements, including deletions, translocations, inversions, and mitotic recombination. In many cases these lesions result in the activation of oncogenic mutations or loss of heterozygosity (LOH) of tumor suppressor genes. The initiating lesion for these types of recombination is DNA strand breaks (590). Thus the generation of strand breaks could well be a necessary step for the evolution of some tumor types, although it is not clear to what extent this might be rate limiting for tumorigenesis. Loss of p53 function is another very common genetic alteration in tumors. In normal cells p53 is induced in response to DNA damage, specifically dsbs, resulting in cell cycle arrest and/or apoptosis of the damage cell. Loss of p53 would render the cells permissive to accumulate additional genetic lesions, for example dsb-induced rearrangements. Severe combined immunodeficient (SCID) mice are severely defective in repair of dsbs and are sensitive to spontaneous and radiation-induced lymphomagenesis. We suggest that these mice represent a very useful model to examine the role of dsbs in tumorigenesis of several different tissues. They will also be useful to dissect the molecular pathway from dsbs to p53 induction to apoptosis in a tissue specific context.
Aim one will determine if scid/scid and scid/+ mice are susceptible to several tissue specific carcinogenesis protocols including skin, liver, and lung. This will address the question of the importance of dsbs in the evolution of different tumor types. It will also reveal if heterozygous carriers of this defect are at increased risk. If so this could have implications for human heterozygous carriers of similar defects.
Aim two will examine the susceptibility of scid/scid mice to specific dsb-inducing chemotherapeutic agents including etoposide, campothecin and bleomycin. This will determine if dsb induction can be a rate limiting step for carcinogenesis.
Aim three will determine if the p53 induction, apoptosis pathway is abnormal in SCID mice.
Aim three will also determine if radiation-induced p53 expression and apoptosis differ substantially between tumor types (skin, liver and lung) and if p53 genotype predicts the apoptotic response of tumor cells in vivo.
Aim four will examine mutational inactivation of p53 in tumors induced in SCID mice to determine if there is unusually strong selection against p53 function. Allelotype analysis in aim five will be used to determine if the frequency of large scale genetic rearrangements, such as deletions, is increased in tumors from SCID mice, as well as to identify alternative genetic pathways which might complement p53 inactivation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA070414-05
Application #
6173467
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Okano, Paul
Project Start
1996-05-10
Project End
2002-03-31
Budget Start
2000-05-01
Budget End
2002-03-31
Support Year
5
Fiscal Year
2000
Total Cost
$303,952
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Gurley, Kay E; Ashley, Amanda K; Moser, Russell D et al. (2017) Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation. Cell Death Differ 24:1853-1860
Moser, Russell; Toyoshima, Masafumi; Robinson, Kristin et al. (2012) MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res 10:535-45
Busch, Stephanie E; Gurley, Kay E; Moser, Russell D et al. (2012) ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. J Pathol 227:298-305
Grosse-Wilde, Anne; Kemp, Christopher J (2008) Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Res 68:6035-7
Bailey, S Lawrence; Gurley, Kay E; Hoon-Kim, Kyung et al. (2008) Tumor suppression by p53 in the absence of Atm. Mol Cancer Res 6:1185-92
Grosse-Wilde, Anne; Voloshanenko, Oksana; Bailey, S Lawrence et al. (2008) TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118:100-10
Gurley, Kay E; Kemp, Christopher J (2007) Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Mol Cancer Res 5:1312-8
Kemp, Christopher J (2005) Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 15:460-73
Philipp-Staheli, Jeannette; Kim, Kyung-Hoon; Liggitt, Denny et al. (2004) Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development. Oncogene 23:905-13
Gurley, K E; Vo, K; Kemp, C J (1998) DNA double-strand breaks, p53, and apoptosis during lymphomagenesis in scid/scid mice. Cancer Res 58:3111-5

Showing the most recent 10 out of 11 publications